Skip to main content

Morning Overview

Stents and bypass surgery didn’t help stable heart patients live longer than medication-first care

Thousands of people with stable heart disease have been asked the same question after an abnormal stress test: open the artery now with a stent or bypass surgery, or start with medication and wait? Nearly a decade of follow-up from a trial that spanned 37 countries now suggests the choice does not change how long they live.

Deaths were 26% in the group assigned to early procedures and 27% in the group assigned to medication-first care, a difference the release describes as essentially the same.

Results from ISCHEMIA-EXTEND

The findings come from ISCHEMIA-EXTEND, the long-term follow-up of the ISCHEMIA trial. A NYU Langone release says the work was published in the Journal of the American Medical Association on Nov. 7 and presented the same day at the American Heart Association Scientific Sessions. It tracked more than 5,000 men and women with stable coronary artery disease at 320 hospitals in 37 countries and recorded 1,071 deaths over follow-up that ran as long as 13 years. Vital status was confirmed for 96% of participants.

The JAMA paper’s key points give the exact enrollment, 5,179 adults, who were randomized starting in August 2012 and followed through December 2025. Median follow-up was nine years. At 11 years, all-cause mortality was 25.8% with the invasive strategy and 26.9% with the conservative one, a difference of 1.0 percentage point with a 95% confidence interval running from a 4.2-point benefit to a 2.1-point harm. The adjusted hazard ratio was 0.97.

The invasive group had stents or bypass surgery soon after an abnormal stress test. The conservative group received procedures only if symptoms worsened or a heart attack occurred. Everyone got cholesterol and blood pressure drugs plus diet and exercise counseling.

Questions the ISCHEMIA-EXTEND data leave open

Cardiovascular mortality at 11 years was 15.8% with the invasive approach and 17.1% with the conservative one, an adjusted hazard ratio of 0.88 whose interval, 0.75 to 1.02, just crosses 1. Noncardiovascular deaths ran the other way, 9.1% against 8.1%. An interim analysis presented in 2022 at a median of 5.7 years had already shown that same offset: fewer cardiovascular deaths with early procedures, more noncardiovascular deaths, and no net difference in all-cause mortality. Causes of death were not adjudicated in that phase of follow-up, MDedge reported, and the rise in noncardiovascular deaths was unexplained. Hochman said at the time that the probability of a lower mortality risk with invasive treatment over 5.7 years was “nil.”

The NYU release lists limits. The extended analysis did not track nonfatal heart attacks, repeat procedures or quality of life after the original trial period, and the findings apply to stable chronic disease, not to people having or threatening to have a heart attack.

Relief of symptoms is a different question

Judith Hochman, the trial’s chair and co-lead author at NYU Langone, said early procedures help relieve chest pain and improve quality of life, but “is unlikely to help patients live longer.” She added that procedures are “lifesaving for patients with heart attacks and threatened heart attacks.” Rebecca Anthopolos of NYU Grossman School of Medicine, the other co-lead author, pointed to “the need for thoughtful discussions between patients with stable heart disease and their healthcare providers” about goals and trade-offs.

The first ISCHEMIA results already pointed that way. The National Heart, Lung, and Blood Institute reported on March 30, 2020, that stents and surgery were no better than medication and lifestyle changes at reducing cardiac events, with 145 deaths in the invasive group and 144 in the medication group after a median follow-up of 3.2 years. Roughly 21% of the conservative group still ended up with a stent or bypass within five years. That crossover is why the comparison is invasive-first against medication-first, not procedures against none.

The NHLBI release also quoted Hochman as saying that stent and surgical procedures carry “a risk of some heart damage,” and John Spertus, M.D., as describing “an impressive, sustainable improvement in patients’ symptoms, function and quality of life” with the invasive approach. The tension between those two statements is the reason the decision is framed as one of goals rather than survival.

Where stents and bypass fit

NHLBI’s treatment guidance describes percutaneous coronary intervention, also called angioplasty, as a procedure that opens arteries narrowed or blocked by plaque, often with a stent, a small mesh tube that keeps the vessel from narrowing again. Bypass grafting, it says, is typically used for severe disease in multiple coronary arteries. The medicines it lists for the conservative path include statins, blood pressure drugs, nitrates for angina and low-dose aspirin.

The study team is now developing tools to tailor decisions using age, extent of disease, heart and kidney function, symptom burden and survival data, according to the NYU release. The 2022 interim readout, posted by NYU Langone’s physician newsletter, had said follow-up would continue into 2025 to sharpen the mortality estimates. Funding came from NIH grant R01HL149888.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.


More from Morning Overview


Morning Overview is reader-supported. Some links in our articles are affiliate links, and we may earn a commission at no extra cost to you. As an Amazon Associate I earn from qualifying purchases. Full disclosure.